Retinopathy Of Prematurity - Pipeline Review, H2 2016

Publisher Name :
Date: 14-Sep-2016
No. of pages: 36

Global Markets Direct's, ‘Retinopathy Of Prematurity - Pipeline Review, H2 2016', provides an overview of the Retinopathy Of Prematurity pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Retinopathy Of Prematurity, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Retinopathy Of Prematurity and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Retinopathy Of Prematurity

  • The report reviews pipeline therapeutics for Retinopathy Of Prematurity by companies and universities/research institutes based on information derived from company and industry-specific sources

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved Retinopathy Of Prematurity therapeutics and enlists all their major and minor projects

  • The report assesses Retinopathy Of Prematurity therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

  • The report summarizes all the dormant and discontinued pipeline projects

  • The report reviews latest news related to pipeline therapeutics for Retinopathy Of Prematurity

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Identify and understand important and diverse types of therapeutics under development for Retinopathy Of Prematurity

  • Identify potential new clients or partners in the target demographic

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

  • Devise corrective measures for pipeline projects by understanding Retinopathy Of Prematurity pipeline depth and focus of Indication therapeutics

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Retinopathy Of Prematurity - Pipeline Review, H2 2016

Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Retinopathy Of Prematurity Overview 6
Therapeutics Development 7
Pipeline Products for Retinopathy Of Prematurity - Overview 7
Retinopathy Of Prematurity - Therapeutics under Development by Companies 8
Retinopathy Of Prematurity - Pipeline Products Glance 9
Late Stage Products 9
Early Stage Products 10
Retinopathy Of Prematurity - Products under Development by Companies 11
Retinopathy Of Prematurity - Companies Involved in Therapeutics Development 12
Biomar Microbial Technologies 12
F. Hoffmann-La Roche Ltd. 13
Retinopathy Of Prematurity - Therapeutics Assessment 14
Assessment by Monotherapy Products 14
Assessment by Target 15
Assessment by Mechanism of Action 17
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Drug Profiles 23
AP-202 - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
IB-09A0133 - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
R-200 - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
ranibizumab - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
Recombinant Protein for Cancer and Diabetic Retinopathy - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Retinopathy Of Prematurity - Dormant Projects 33
Retinopathy Of Prematurity - Discontinued Products 34
Appendix 35
Methodology 35
Coverage 35
Secondary Research 35
Primary Research 35
Expert Panel Validation 35
Contact Us 35
Disclaimer 36

List of Tables

Number of Products under Development for Retinopathy Of Prematurity, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Late Stage Development, H2 2016 9
Comparative Analysis by Early Stage Development, H2 2016 10
Products under Development by Companies, H2 2016 11
Retinopathy Of Prematurity - Pipeline by Biomar Microbial Technologies, H2 2016 12
Retinopathy Of Prematurity - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 13
Assessment by Monotherapy Products, H2 2016 14
Number of Products by Stage and Target, H2 2016 16
Number of Products by Stage and Mechanism of Action, H2 2016 18
Number of Products by Stage and Route of Administration, H2 2016 20
Number of Products by Stage and Molecule Type, H2 2016 22
Retinopathy Of Prematurity - Dormant Projects, H2 2016 33
Retinopathy Of Prematurity - Discontinued Products, H2 2016 34

List of Figures

Number of Products under Development for Retinopathy Of Prematurity, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Early Stage Products, H2 2016 10
Assessment by Monotherapy Products, H2 2016 14
Number of Products by Targets, H2 2016 15
Number of Products by Stage and Targets, H2 2016 15
Number of Products by Mechanism of Actions, H2 2016 17
Number of Products by Stage and Mechanism of Actions, H2 2016 17
Number of Products by Routes of Administration, H2 2016 19
Number of Products by Stage and Routes of Administration, H2 2016 19
Number of Products by Molecule Types, H2 2016 21
Number of Products by Stage and Molecule Types, H2 2016 21
  • Global Ophthalmics Partnering 2010-2017: Deal trends, players and financials
    Published: 01-Feb-2017        Price: US 2995 Onwards        Pages: 500
    "Delivery of this report will take 1-3 days after purchase." Summary The Global Ophthalmics Partnering 2010-2017: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the ophthalmics partnering deals and agreements entered into by the worlds leading healthcare companies Description Global Ophthalmics Partnering 2010 to 2017 provides the full collection of Ophthalmic......
  • Global Age-related Macular Degeneration Partnering 2010 to 2017
    Published: 01-Feb-2017        Price: US 1495 Onwards        Pages: 100
    "Delivery of this report will take 1-3 days after purchase." Summary Provides understanding and access to the age-related macular degeneration partnering deals and agreements entered into by the worlds leading healthcare companies. Description The Global Age-related Macular Degeneration Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by ......
  • Global Glaucoma Partnering 2010 to 2017
    Published: 01-Feb-2017        Price: US 1495 Onwards        Pages: 100
    "Delivery of this report will take 1-3 days after purchase." Summary Provides understanding and access to the glaucoma partnering deals and agreements entered into by the worlds leading healthcare companies. Description The Global Glaucoma Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. ......
  • Global Retinopathy Partnering 2010 to 2017
    Published: 01-Feb-2017        Price: US 1495 Onwards        Pages: 100
    "Delivery of this report will take 1-3 days after purchase." Summary Provides understanding and access to the retinopathy partnering deals and agreements entered into by the worlds leading healthcare companies. Description The Global Retinopathy Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies.......
  • Global Dry Eye Partnering 2010 to 2017
    Published: 01-Feb-2017        Price: US 1495 Onwards        Pages: 100
    "Delivery of this report will take 1-3 days after purchase." Summary Provides understanding and access to the dry eye partnering deals and agreements entered into by the worlds leading healthcare companies. Description The Global Dry Eye Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. ......
  • Global Latanoprost Sales Market Report 2017
    Published: 13-Jan-2017        Price: US 4000 Onwards        Pages: 117
    Notes: Sales, means the sales volume of Latanoprost Revenue, means the sales value of Latanoprost This report studies sales (consumption) of Latanoprost in Global market, especially in United States, China, Europe and Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering - Pfizer - Teva Pharmaceuticals - Greenstone - Novartis - Mylan - ......
  • China Ophthalmic Drug Market Research Report 2017
    Published: 13-Jan-2017        Price: US 3200 Onwards        Pages: 114
    Notes: Sales, means the sales volume of Ophthalmic Drug Revenue, means the sales value of Ophthalmic Drug This report studies Ophthalmic Drug in China market, focuses on the top players in China market, with capacity, production, price, revenue and market share for each manufacturer, covering - Novartis - Allergan - Santen - Pfizer - Merck - Roche - Bayer - Senju - Regeneron - Valeant - Ozur......
  • Europe Ophthalmic Drug Market Report 2017
    Published: 12-Jan-2017        Price: US 3900 Onwards        Pages: 117
    Notes: Sales, means the sales volume of Ophthalmic Drug Revenue, means the sales value of Ophthalmic Drug This report studies sales (consumption) of Ophthalmic Drug in Europe market, especially in Germany, France, UK, Russia, Italy, Spain and Benelux, focuses on top players in these countries, with sales, price, revenue and market share for each player in these Countries, covering - Novartis - Allergan - Santen - Pfizer - Merck......
  • China Latanoprost Market Research Report 2017
    Published: 12-Jan-2017        Price: US 3200 Onwards        Pages: 105
    Notes: Sales, means the sales volume of Latanoprost Revenue, means the sales value of Latanoprost This report studies Latanoprost in China market, focuses on the top players in China market, with capacity, production, price, revenue and market share for each manufacturer, covering - Pfizer - Teva Pharmaceuticals - Greenstone - Novartis - Mylan - Taj Pharmaceuticals - Apotex - Sun Pharma - Squibb - ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs